Chapter Five – Reprogramming and Carcinogenesis—Parallels and Distinctions
2014 (English)In: International Review of Cell and Molecular Biology, ISSN 1937-6448, Vol. 308, 167-203 p.Article in journal (Refereed) Published
Rapid progress made in various areas of regenerative medicine in recent yearsoccurred both at the cellular level, with the Nobel prize-winning discovery of reprogramming(generation of induced pluripotent stem (iPS) cells) and also at the biomateriallevel. The use of four transcription factors, Oct3/4, Sox2, c-Myc, and Klf4 (calledcommonly “Yamanaka factors”) for the conversion of differentiated cells, back tothe pluripotent/embryonic stage, has opened virtually endless and ethically acceptablesource of stem cells for medical use. Various types of stem cells are becomingincreasingly popular as starting components for the development of replacement tissues,or artificial organs. Interestingly, many of the transcription factors, key to themaintenance of stemness phenotype in various cells, are also overexpressed in cancer(stem) cells, and some of them may find the use as prognostic factors. In this review,we describe various methods of iPS creation, followed by overview of factors known tointerfere with the efficiency of reprogramming. Next, we discuss similarities betweencancer stem cells and various stem cell types. Final paragraphs are dedicated to interactionof biomaterials with tissues, various adverse reactions generated as a result ofsuch interactions, and measures available, that allow for mitigation of such negativeeffects.
Place, publisher, year, edition, pages
Elsevier, 2014. Vol. 308, 167-203 p.
Bioglass; Senescence; Transdifferentiation; Yamanaka factor; iPS cells; p53
Cell and Molecular Biology
IdentifiersURN: urn:nbn:se:liu:diva-109693DOI: 10.1016/B978-0-12-800097-7.00005-1ISI: 000333378100005PubMedID: 24411172OAI: oai:DiVA.org:liu-109693DiVA: diva2:740622